Ascendis Pharma A (ASND) Change in Account Payables (2012 - 2026)

Ascendis Pharma A has disclosed Change in Account Payables across 15 years of filings, most recently posting -$24.6 million for Q1 2026.

• Change in Account Payables for Q1 2026 came in at -$24.6 million, up 42.53% year-over-year; the trailing twelve-month figure through Mar 2026 was -$26.9 million (down 540.89% YoY), and the FY2025 annual result was -$49.2 million, down 270.85% from the prior year.
• Change in Account Payables came in at -$24.6 million for Q1 2026 at Ascendis Pharma A, down from -$10.7 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $48.1 million in Q4 2024 to a low of -$42.9 million in Q1 2025.
• The 5-year median for Change in Account Payables is -$4.9 million (2022), against an average of $535476.0.
• Peak annual rise in Change in Account Payables reached 544.5% in 2024, while the deepest fall reached 275.44% in 2024.
• Ascendis Pharma A's Change in Account Payables stood at $23.9 million in 2022, then sank by 145.28% to -$10.8 million in 2023, then surged by 544.5% to $48.1 million in 2024, then sank by 122.28% to -$10.7 million in 2025, then sank by 130.03% to -$24.6 million in 2026.
• The last three Change in Account Payables figures came in at -$24.6 million (Q1 2026), -$10.7 million (Q4 2025), and -$8.8 million (Q3 2025), per Business Quant data.